The article focuses on a urine-based test, MyProstate-Score 2.0 (MPS2), which shows promising accuracy in diagnosing high-grade prostate cancer, potentially reducing the need for unnecessary biopsies or imaging and minimizing the harms associated with prostate cancer screening.